• Home
  • NEW DAY MEDICINE
  • 4 (66) 2024
  • 147 -4 (66) 2024 - Egamova I.N., Rahimova V.Sh. - USE OF SERUM MARKER WFA+-M2BP TO DETERMINE THE DEGREE OF FIBROSIS IN PATIENTS WITH VIRAL CIRRHOSIS OF THE LIVER

147 -4 (66) 2024 - Egamova I.N., Rahimova V.Sh. - USE OF SERUM MARKER WFA+-M2BP TO DETERMINE THE DEGREE OF FIBROSIS IN PATIENTS WITH VIRAL CIRRHOSIS OF THE LIVER

USE OF SERUM MARKER WFA+-M2BP TO DETERMINE THE DEGREE OF FIBROSIS IN PATIENTS WITH VIRAL CIRRHOSIS OF THE LIVER

Egamova I.N. - Research Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Uzbekistan, Tashkent

Rahimova V.Sh. - Research Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Uzbekistan, Tashkent

Ibadullaeva N.S. - Research Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Uzbekistan, Tashkent

Xikmatullaeva A.S. - Research Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Uzbekistan, Tashkent

Resume

Chronic viral hepatitis C is relevant both throughout the world and in Uzbekistan. This article describes the diagnostic effectiveness of the serum marker M2BP as a non-invasive method in diagnosing the stage of liver fibrosis.

Keywords: chronic viral hepatitis C, liver cirrhosis, liver fibrosis, serum markers, M2BP markers, non-invasive diagnostics.

First page

808

Last page

814

For citation: Egamova I.N., Rahimova V.Sh., Ibadullaeva N.S., Xikmatullaeva A.S. - USE OF SERUM MARKER WFA+-M2BP TO DETERMINE THE DEGREE OF FIBROSIS IN PATIENTS WITH VIRAL CIRRHOSIS OF THE LIVER//New Day in Medicine 4(66)2024 808-814 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Эгамова И.Н., Рахмова В.Ш., Ярмухамедова Н.А., Волкова Н.Н. / современные методы определения фиброза печени // Достижения науки и образования ISSN: 2413-2071 2020;7(61):39-42.
  2. Atsushi Kuno, Yuzuru Ikehara, Yasuhito Tanaka, Kiyoaki Ito, Atsushi Matsuda, Satoru Sekiya, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Scientific Reports. 2013 Volume 3, Article number: 1065.
  3. Ching-I Huang, Chung-Feng Huang, Ming-Lun Yeh, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hseih, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung Journal of Medical Sciences. 2017 Aug;33(8):394-399.
  4. EASL: Clinical Practice Guidelines: Management of hepatitis С virus infection. Journal of Hepatjlogy. 2014 Feb;60(2):392–420. DOI: 10.1016/j.jhep.2013.11.003.
  5. Erkin M. et al. The challenge of emerging and re-emerging infectious diseases in Uzbekistan: study of rickettsiosis using pcr diagnostic method //European science
  6. Inoue T, Tsuzuki Y, Iio E, Shinkai N, Matsunami K, Fujiwara K, et al. Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. Jpn. J. Infect. Dis. 2018 May;24;71(3):177-183. DOI: 10.7883/yoken.JJID.2017.459.
  7. Ishida H, Suetsugu A, Nakamura M, Tauchi R, Nakayama J, Katano Y, et al. Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin. Rinsho Byori. 2015 Aug;63(8):901-906.
  8. Koji Fujita, Noriyuki Kuroda, Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Takako Nomura, et al. Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection. J. Clin. Med. 2018 Sep;7(9):267. DOI: 10.3390/jcm7090267.
  9. Kuno, A. et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 3, 1065 (2013).
  10. Lung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai and Man-Fung Yuen. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and Translational Gastroenterology. 2018 Jun;9(6):163. DOI: 10.1038/s41424-018-0020-9.
  11. Ming-Yu Zhu, Pei-Zhan Chen, Jing Li, De-Min Yu, Dao Huang, Xue-Juan Zhu, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J.Med.Virol. 2018 Apr;90(4):721–729. DOI:10.1002/jmv.25010.
  12. Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016 Nov;10(6):956-964. Epub 2016 Jul 19.
  13. Narimatsu, H. Development of M2BPGi: A novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev. Proteomics 12, 683–693. https://doi.org/10.1586/14789450.2015.1084874 (2015).review. 2018. №. 5-6.
  14. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2015;36: 293–301.
  15. Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, et al. Serum WFA (+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016 Jan;43(1):114-124. DOI: 10.1111/apt.13431.
  16. Weber, A., Boege, Y., Reisinger, F. & Heikenwalder, M. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med. Wkly. 141, w13197 (2011).
  17. Zou X, Zhu M, Yu DM, Li W, Zhang DH, Lu FJ, et al. Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int. 2017 Jan;37(1):35-44. DOI: 10.1111/liv.13188.

    file

    download